

DOI: 10.53555/ks.v12i5.3194

Pharmacokinetic Properties of Bioactive Compounds of *Aloe vera* against Pregnancy-Associated Plasma Protein A (PAPP-A) inducing Triple-Negative Breast Cancer

Asif Bilal¹, Fouzia Tanvir^{1*}, Sibtain Ahmad^{2,3*}, Noreen Kanwal¹, Hamza Zulfiqar⁴, Rabia Ishaq^{5,6}

¹Department of Zoology, University of Okara, Okara Pakistan

²Institute of Animal and Dairy Sciences, Faculty of Animal Husbandry, University of Agriculture, Faisalabad, Pakistan

³Center for Advanced Studies Agriculture and Food Security (CAS-AFS), University of Agriculture, Faisalabad, Pakistan

⁴Department of Animal Science, Faculty of Animal and Agricultural Sciences, Universitas Diponegoro, Semarang 50275, Indonesia

⁵Department of Zoology, University of Sargodha, Sargodha Pakistan

⁶Higher Education Department, Government Associate college for women 75/SB Sargodha, Pakistan

***Corresponding Authors:** Fouzia Tanvir

*Email: fouzia.tanvir@uo.edu.pk : Sibtain Ahmad: dr_sibtainhmd6@uaf.edu.pk

Abstract: This study aims to discover the mechanisms by which phytoactive compounds from *Aloe vera* exert anti-breast cancer effects through in silico analysis, exploring their potential as promising therapeutic candidates against triple-negative breast cancer in particular. For this purpose, the pregnancy associated plasma protein-A (PAPP-A) was chosen based on their high protein-protein interaction scores. The protein sequence was retrieved from databases such as NCBI and UniProt. Structural modeling was performed using the SWISS-MODEL platform, Structural validation identified by the SAVES server and TM-align. Ligand preparations involved selecting ligands including aloenin, aloe-emodin, aloeresin D, aloesin, aloin side A, anthraquinones, naphthoquinones, and phenol, phytosterol, and terpenoids from the ChEBI database and filtering for specific criteria. Protein-ligand docking analysis was carried out using the PyRx program. ADME analysis performed by SwissADME. The target protein PAPP-A is a protease involved in the regulation of fetal growth and TNBC. Several compounds, such as aloe-emodin, aloeresin D, phenol, anthraquinone, naphthoquinones, and aloin side A, exhibit promising binding potential towards the target protein, with an affinity of -7.9 kcal/mol and rmsd scores of 21.079 and 18.688 angstroms, respectively. The results of this study provide a solid starting point for the development of PAPP-A inhibitors and offer potential therapeutic applications across therapeutics. It provides novel insights into candidates' properties as potential PAPP-A inhibitors, highlighting molecules like aloenin, aloesin and anthraquinones for further preclinical development against aggressive triple-negative breast cancer driven by this pathway pending more research.

Keywords: *Aloe vera*, Phytochemicals, PAPP-A, Molecular docking, Triple-negative breast cancer

INTRODUCTION

Triple-negative breast cancer (TNBC) is a distinct subtype of breast cancer that lacks the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It accounts for approximately 10-20% of all breast cancer cases and is associated with aggressive tumor behavior and poorer prognosis compared to other breast cancer subtypes (Li et al., 2017).

TNBC tends to occur more frequently in younger women, particularly those of African-American descent (Huo et al., 2012). It has been linked to a higher prevalence of BRCA1 gene mutations, which play a crucial role in DNA repair mechanisms. Additionally, TNBC is more likely to affect women with a family history of breast and ovarian cancer (Foulkes et al., 2010).

TNBC often presents as a more aggressive form of breast cancer, characterized by a higher rate of lymph node involvement, larger tumor size, and increased likelihood of distant metastasis (Dent et al., 2007; Bilal et al., 2021). Due to the absence of hormone receptors and HER2 overexpression, targeted therapies such as hormonal therapy and HER2-targeted agents are ineffective in TNBC treatment.

TNBC is a heterogeneous disease with diverse molecular subtypes. Gene expression profiling has identified several molecular subtypes of TNBC, including basal-like 1 and 2, mesenchymal-like, and luminal androgen receptor (Lehmann et al., 2011). These subtypes exhibit distinct gene expression patterns and are associated with different clinical outcomes and treatment responses (Sajjad et al., 2024).

Chemotherapy remains the primary treatment modality for TNBC due to the lack of targeted therapies. Standard chemotherapy regimens, such as anthracyclines and taxanes, are commonly used in the neoadjuvant and adjuvant settings (von Minckwitz et al., 2012). However, the response rates to chemotherapy vary among patients, highlighting the need for personalized treatment approaches (Noor et al., 2024).

Recent advances in understanding the molecular mechanisms of TNBC have paved the way for the development of novel targeted therapies. Poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib and talazoparib, have shown promising results in BRCA1/2-mutated TNBC (Robson et al., 2017). Immune checkpoint inhibitors, including pembrolizumab and atezolizumab, have demonstrated efficacy in TNBC patients with high levels of tumor-infiltrating lymphocytes (Schmid et al., 2020).

Pregnancy-associated plasma protein-A (PAPP-A), also known as Pappalysin-1, is a glycoprotein enzyme that plays a crucial role in various biological processes, particularly during pregnancy (Afzal et al., 2024). However, recent research has shed light on the damaging effects of PAPP-A in certain pathological conditions. PAPP-A is primarily secreted by the placenta and is involved in the regulation of insulin-like growth factor (IGF) signaling. During pregnancy, PAPP-A acts as a protease that cleaves insulin-like growth factor-binding protein-4 (IGFBP-4), leading to the release of bioactive IGFs (Conover, 2015).

Studies have identified elevated levels of PAPP-A in the synovial fluid and cartilage of Osteoarthritis patients (Sowers et al., 2004). Given the detrimental effects of dysregulated PAPP-A in various pathological conditions, targeting PAPP-A has emerged as a potential therapeutic strategy including cardiovascular diseases (Jespersen et al., 2019). In cancer research, PAPP-A inhibitors have shown promise in preclinical studies, suggesting their potential as novel anti-cancer agents (Kessler et al., 20216).

It is not only involved in pregnancy-related processes but has also gained attention for its potential involvement in cancer development, including breast cancer. Breast cancer is the most commonly diagnosed cancer among women worldwide (Ferlay et al., 2018).

The overexpression of PAPP-A may contribute to tumor growth, invasion, and metastasis. PAPP-A interacts with insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) to regulate cell growth and survival. In breast cancer, the dysregulation of this interaction can have detrimental effects. PAPP-A proteolytically cleaves IGFBP-4, leading to increased bioavailability of IGFs, which can promote cell proliferation and survival (Moverare-Skrtic et al., 2017). PAPP-A expression was found to be significantly higher in breast cancer tissues compared to adjacent normal tissues (Marques et al., 2016).

Recent studies have shed light on the role of PAPP-A in TNBC. It has been found that PAPP-A expression is significantly higher in TNBC tissues compared to other breast cancer subtypes (Kong et al., 2019). PAPP-A is known to interact with insulin-like growth factors (IGFs) and their binding proteins (IGFBPs), regulating cell growth and survival. PAPP-A's proteolytic activity can cleave IGFBP-4, resulting in the release of IGFs and promoting cell proliferation and survival (Moverare-Skrtic et al., 2017; Kong et al., 2019).

Pregnancy-associated plasma protein-A (PAPP-A) has emerged as a potential player in the unique landscape of triple-negative breast cancer. Its upregulation in TNBC tissues suggests its involvement in tumor development and progression. PAPP-A's interaction with IGFs and IGFBPs may contribute to the aggressive behavior observed in this subtype.

Aims and Objectives

To elucidate the molecular mechanisms underlying the anti-breast cancer activity of phytoactive compounds of *Aloe vera* by in-silico analysis that may have a beneficial effect as a promising candidate for cancer therapy based on its critical role in treating triple-negative breast cancer.

MATERIALS AND METHODS

Selection of Proteins

The Pregnancy associated plasma protein-A (PAPP-A) was selected for the experiment by Protein-protein interaction and docking analysis. The selected proteins have the highest docking score and interaction score.

Retrieval of Protein

The sequence of protein was collected from several databases, particularly NCBI (<http://www.ncbi.nlm.nih.gov>), and UniProt (<https://www.uniprot.org>) in Fasta format. This protein ID was KAG8518848.1.

Protein Modeling

In order to anticipate structural stability and variations, 3D configurations of both wild-type and mutant proteins were constructed using the SWISS-MODEL platform (<http://swissmodel.expasy.org>). The native structure was reconstructed using homology modeling techniques, and a single-point mutation was subsequently applied in the pymol (<https://pymol.org/2>). Chiron (<https://dokhlab.med.psu.edu/chiron/login.php>) was used to the energy of a selection of wild and mutant models of both proteins. The individual improved protein models are presented at the conclusion, with each model available for download as a PDB file.

Structural validation and RMSD calculation

Using the SAVES server (<https://saves.mbi.ucla.edu>), the structural model was chosen and put through a structural validation process. PROCHECK and ERRAT are incorporated into SAVES to confirm the overall quality of the 3D model. The RAMACHANDRAN plot that ProCHECK produced was another tool used to assess the quality of the model. The three-dimensional validation assesses the agreement between a protein's primary and tertiary structures. Then, the structures of wild-type and mutant proteins were compared using TM-align (<https://zhanglab.ccmb.med.umich.edu/TM-align>). This method computes the root mean square deviation (RMSD) and the template modeling score (TM-score) using a superposition. A number value between 0 and 1, which represents a perfect match between the two structures, is provided by the TM-score. Greater structural divergence between wild-type and mutant forms is indicated by a higher RMSD value. In order to identify

the preferred region of amino acids, the RAMAHANDRAN Plot additionally took into account the dihedral angle of atoms in amino acid residues.

Ligand Preparations

For the selection of bioactive compounds including aleonin, aloemodin, aloeresin D, aloesin, aloinisin A, anthraquinones, naphthoquinones, phenol, phytosterol, and terpenoids were utilized the ChEBI database (<http://www.ebi.ac.uk/chebi/>), which contains commercially-available compounds for virtual screening purposes. From this large library containing billions of molecules, we focused our search on compounds matching criteria that increased the likelihood of binding at our target receptors. Specifically, we filtered for chemicals within a certain molecular weight range and containing functional groups known to participate in common protein-ligand binding interactions such as hydrogen bonding, aromatic interactions and charged motifs.

Protein-Ligand docking analysis

Molecular docking was performed to find ligand-protein interaction and for finding potential ligands. For this, we docked all selected ligands with the protein using the PyRx program (<https://pyrx.sourceforge.io>). The Lamarckian genetic algorithm (LGA) which incorporates AutoDock and AutoDock Vina, was applied for virtual ligand screening. The 10 greatest exclusive values were calculated for each ligand, with the active parameters set to the highest grid size of the center. The remaining parameters were set as default. The AutoDock tools were used to convert the PDB files to PDBQT format and calculate the binding affinities. The chemical structures of ligands were obtained from PubChem (<https://pubchem.ncbi.nlm.nih.gov/>) database, for virtual screening, Discovery Studio (<https://discover.3ds.com/discovery-studio-visualizerdownload>) version 3 was used for 2D and 3D interaction of ligands with protein. They showed the size and location of bonding sites, hydrogen bond interactions, hydrophobic interactions, and bonding distances of a docked ligand.

ADME Analysis Test

The initial screening of ligands was conducted using a web-based program, named SwissADME. The molecular weight, lipophilicity, Log P value, hydrogen bond donors, and hydrogen acceptors are the five factors were examined by this test. Ligands violation denotes that the drug is unfit for production, which is carried out by Lipinski's regulation.

Pharmacokinetics

The drug probability of various cannabinoids with binding energies lower than the control is analyzed using the SwissADME program, and six features are then taken into account to build a bioavailability radar. We consider the following six factors: size, polarity, saturation, lipophilicity, solubility, and flexibility. Any divergence from the pink-shaded area, which represents the ideal values of the six parameters, suggests that the ligand should not be orally accessible. Brain access and gastric adsorption are two crucial pharmacokinetic behaviors at different phases of the drug development process. the Brain Or IntestinaL EstimateD permeation method (BOILED-Egg) is an accurate predictive model that computes the lipophilicity and polarity of tiny compounds. Predictions of both gut and brain penetration are derived from physical-chemical descriptors and subsequently translated into accurate, fast-running, and conceptually simple molecular designs by means of models. There are numerous uses for boiled eggs. It is helpful for drug development's early-stage library filtering through the final assessment. It is acquired using the SwissADME instrument.

RESULTS

Protein-Modeling

The plot maps the dihedral angles phi and psi of each peptide bond, allowing visualization of preferred and allowed regions for residues to adopt based on steric constraints. Most points falling within favored areas indicates the overall structure is physically reasonable without inappropriate geometries. As seen in the plot provided, a vast majority of PAPP-A residues lie comfortably within the core favored regions in the upper left and lower right quadrants as expected for protein backbones. Only a small fraction occupies less populated allowed areas, suggesting high stereospecificity without improbable conformations induced by modeling errors.

Additionally, no observations fall within the outlier region outside favored/allowed zones often representing inaccurate structural elements. This provides strong evidence the computational homology model has captured PAPP-A's fold reliably without obvious issues that could compromise results from simulations or docking studies performed using this structure.

The Ramachandran analysis thus verifies the model conforms to common patterns seen in known x-ray crystal structures, lending confidence it can reasonably represent the native protein conformation and topology for interaction or dynamic investigations at an atomic level of detail. Continued assessment using complementary validation tools will help characterize model quality further prior to its application. The plot confirms acceptable stereochemistry within the PAPP-A computational structure given appropriate torsional distributions observed, justified its potential utility as a representative receptor for virtual screening or mechanistic analyses of this drug target going forward (Figure 1).

Ramachandran Plot




Figure 1: Protein Modeling Analysis of PAPP-A protein

Molecular docking analysis

The molecular docking study provides insight into how well aloenin may bind to and interact with PAPP-A. The compound aloenin shows a binding affinity of -7.3 kcal/mol, indicating a moderately favorable therapeutic interaction. The root-mean-square deviation (RMSD) scores help evaluate how closely the docked ligand poses match the initial input structure. The RMSD values of 49.787 Å for the upper bound and 46.361 Å for the lower bound, while somewhat high, can be acceptable ranges depending on the size of the ligand. RMSD under 5 Å is generally preferred for tighter binding ligands. With tweaks focusing on the aloenin pharmacophore, lead optimization seems promising for obtaining clinical candidates. Inhibiting PAPP-A's protease activity could prove clinically useful (Figure 2A).

Aloe-emodin may interact with PAPP-A at the molecular level. Based on the findings, aloe-emodin demonstrates good binding potential towards PAPP-A, with a computed binding affinity of -7.4 kcal/mol. It indicates the ligand and protein are predicted to form a stable complex driven by favorable non-covalent binding forces. The root-mean-square deviation scores of 70.573 Å and 68.287 Å for the upper and lower bounds, respectively, give a sense of how closely the ligand's docked conformation resembles its initial input structure. Continued molecular modeling will help elucidate important structure-activity relationships to guide medicinal chemistry efforts. These results establish a promising starting point meriting deeper evaluation of aloe-emodin as a lead compound for inhibiting the PAPP-A target (Figure 2B).

The binding of Aloeresin D achieves a respectable binding affinity of -7.3 kcal/mol for the protein target. This free energy of binding implies the ligand-protein complex would form spontaneously and have stability driven by non-covalent attractive forces between them. The RMSD scores of 26.988 Å and 24.102 Å for the upper and lower bounds respectively give an idea of how closely the docked poses mimic the natural conformation of aloeresin D. A thoughtful iterative process of molecular modeling, synthesis and testing could support medicinal chemistry advancements toward novel PAPP-A inhibitors. If successful, such allosteric modulators may prove useful for conditions where regulating this protease activity could provide benefits. The docking predicts aloeresin D merits more rigorous evaluation and holds potential as a relevant chemical scaffold for developing selective pharmaceuticals targeting PAPP-A (Figure 2C).

Aloesin's binding properties that are encouraging for further pursuing it as a lead compound. Aloesin achieves a binding affinity of -7.9 kcal/mol for PAPP-A, implying a stable, favored complex will form between ligand and protein driven by attractive intermolecular forces. The rmsd values of 21.079 Å and 18.688 Å for the upper and lower bounds respectively indicate aloesin's docked poses are reasonably close matches to its original conformation when binding. This docking study offers aloesin as a

potential scaffold deserving of more rigorous appraisal. Refining it as outlined could support developing selective PAPP-A pharmaceuticals with applications in problematic clinical contexts (Figure 2D).

Aloinaside A demonstrates quite favorable binding potential towards PAPP-A, with an estimated affinity of -8.6 kcal/mol. This strongly exothermic free energy of binding implies a very stable, favorably driven association between ligand and protein upon complex formation. The root-mean-square deviation scores of 6.077Å and 3.348Å for the upper and lower bounds respectively indicate aloinaside A's docked poses closely mimic its natural conformation when binding suitably within the active site. These low rmsd values are certainly encouraging for attaining desirable selectivity and potency. Considering the very strong affinity measured coupled with optimal rmsd readings achieved, the data lends promising initial evidence that aloinaside A warrants extensive additional investigation. It provides aloinaside A as an apt molecular scaffold well deserving of intensive further evaluation towards developing customized PAPP-A biopharmaceuticals (Figure 2E).

These molecular docking results offer valuable information on how the anthraquinone group may interact with the target protein PAPP-A. Anthraquinones demonstrate a respectable binding affinity of -7.4 kcal/mol for PAPP-A. This free energy value implies the anthraquinones-protein complex will form spontaneously, driven by favorable binding interactions. The root-mean-square deviation scores between 4.631Å to 0.103Å for the upper and lower bounds respectively suggest anthraquinones are well-suited to assimilate fitting binding orientations within PAPP-A's active site. These low rmsd readings point to anthraquinones retaining compatible conformations that maximize important interactions. Considering the acceptable affinity exhibited coupled with favorable rmsd scores achieved, this preliminary data presents anthraquinones as a drug-like chemical class holding promise for developing selective PAPP-A inhibitors. This is as a pharmaceutically-relevant scaffold worthwhile of rigorous additional evaluation towards customized PAPP-A modulators with broad applicability potential (Figure 2F).

Naphthoquinones demonstrate a respectable binding affinity of -7.2 kcal/mol. This signifies spontaneous complex formation driven by stabilizing non-covalent interactions between ligand and protein. The rmsd values of 52.109Å and 50.212Å for the upper and lower bounds respectively indicate naphthoquinones can assimilate conformations well-matched to the native structure when aligning within the active site. While not optimal, these rmsd readings fall within acceptable tolerances. Considering the favorable affinity exhibited and rmsd scores achieved, this preliminary data offers naphthoquinones as a biologically-relevant scaffold meriting rigorous follow-up investigation towards personalized PAPP-A modulators (Figure 2G). Specifically, phenol achieves a moderate binding affinity of -5.1 kcal/mol for PAPP-A. While not as strongly exothermic as some others examined, this free energy value implies the phenol-protein complex forms predominantly driven by stabilizing binding forces. The root-mean-square deviation scores between 15.82Å to 16.535Å for the upper and lower bounds respectively suggest phenol aligns workably within PAPP-A's active site. These rmsd readings fall within a satisfactory tolerance indicating phenol's docked poses mimic its natural conformation. These docking results present phenol as a pharmaceutically-plausible lead deserving refinement toward customized PAPP-A modulators with applications across therapeutics (Figure 2H). Phytosterol's binding interaction with the key protein target PAPP-A based on molecular modeling studies. Phytosterol demonstrates an excellent predicted binding affinity of -8.7 kcal/mol towards PAPP-A. This strongly favorable free energy of binding implies a very stable complex will form upon ligand-target association. The low root-mean-square deviation values ranging from 2.876Å to 1.703Å for the upper and lower bounds respectively indicate phytosterol's docked poses within the active site closely resemble its native conformation. This analysis provides phytosterol as a biologically-plausible molecular framework worthy of rigorous additional refinement toward next-generation personalized PAPP-A regulators (Figure 2I).

'Terpenoids' binding potential towards the important target protein PAPP-A. Promisingly, terpenoids demonstrate a favorable predicted binding affinity of -8.0 kcal/mol. This signifies stable complex formation will be driven by productive biochemical interactions. The low root-mean-square deviation scores ranging from 7.382Å to 1.703Å for the upper and lower bounds respectively suggest terpenoids assimilate conformations well-aligned to suit key sections within PAPP-A's binding pocket. These optimal RMSD values bode well for attaining desirable selectivity and potency. It means that the terpenoids as a pharmaceutically-relevant chemotype deserving of intensive additional refinement towards next-generation personalized PAPP-A modulators with broad applicability potential (Figure 2J).




Figure 2: 2D protein-ligand interaction

Upon analyzing the molecular docking results, it is evident that various compounds, such as aloenin, aloe-emodin, aloeresin D, aloesin, aloinaside A, anthraquinones, naphthoquinones, and phenol, exhibit promising binding potential towards the target protein PAPP-A. These compounds demonstrate favorable binding affinities, ranging from -5.1 kcal/mol to -8.6 kcal/mol, indicating stable and favorable interactions. Although some compounds have higher root-mean-square deviation (RMSD) scores, falling within an acceptable range, they still display the ability to adopt fitting poses within the active site of PAPP-A. This suggests that further investigation and optimization of these compounds, such as through modifications and extensions, could enhance their potency and selectivity. The findings of this study provide a solid starting point for the development of PAPP-A inhibitors and offer potential therapeutic applications in conditions involving dysregulated protease activity. Here is all 3D structure of these bioactive compounds respectively.




Figure 3: 3D structure of protein-ligand interaction

In the provided table, each row represents a different compound, referred to as ligands, while the columns display crucial information about their binding affinity and root mean square deviation (rmsd) values. The binding affinity indicates the strength of the interaction between the ligand and PAPP-A, while the rmsd values provide insights into the structural alignment between the ligand and the target protein.

The molecular docking study analyzed the binding affinity of various compounds to the pappalysin-1 protein target. Aloeemodin showed good binding with an affinity of -7.4 kcal/mol. The root-mean-square deviation (rmsd) between the bound complex and initial ligand poses was 70.573 angstroms for the upper bound and 68.287 angstroms for the lower bound. Aloenin had a similar affinity of -7.3 kcal/mol, with rmsd values of 49.787 angstroms and 46.361 angstroms for the upper and lower bounds. Aloeresin D also exhibited an affinity of -7.3 kcal/mol when docked, and rmsd scores of 26.988 angstroms and 24.102 angstroms.

Aloesin showed the highest binding of the compounds tested, with an affinity of -7.9 kcal/mol and rmsd scores of 21.079 angstroms and 18.688 angstroms. Alinoside A followed with very favorable binding at -8.6 kcal/mol, and low rmsd values between 6.077-3.348 angstroms. The anthraquinone group and naphthoquinones also interacted well with pappalysin-1, with affinities around -7.4 kcal/mol and -7.2 kcal/mol respectively.

The compound phenol aligned moderately well with an affinity of -5.1 kcal/mol and 15.82-16.535 angstrom rmsd range. Phytosterols and terpenoids showed the strongest interactions of all compounds studied, binding at -8.7 kcal/mol and -8.0 kcal/mol respectively, with low rmsd scores between 1.703-7.382 angstroms indicating stable conformations. These results suggest these classes of natural products may serve as promising starting points for developing pappalysin-1 inhibitory agents. These results provide valuable insights into the potential interactions between the compounds and PAPP-A. The binding affinities, indicated by negative values, suggest that these ligands have a favorable affinity for PAPP-A. The lower the value, the stronger the interaction.

Additionally, the rmsd values give us an idea of the structural alignment between the ligands and PAPP-A, measured in angstroms. The rmsd/ub and rmsd/lb refer to the upper bound and lower bound limits, respectively, of the rmsd values.

Based on these results, we can observe that several compounds, such as Pappalysin-1_aloesin, Pappalysin-1_aloinoside_A, and Pappalysin-1_phytosterol, exhibit high binding affinities with PAPP-A, indicating a potentially strong interaction. Furthermore, the rmsd values suggest that these ligands achieve relatively good structural alignment with the protein.

It is important to note that further analysis and experimental validation are necessary to confirm the functional significance of these interactions. Molecular docking results provide valuable initial insights, but additional studies are required to fully understand the biological implications and potential therapeutic applications of these compound-PAPP-A interactions.

In conclusion, the provided docking results offer a glimpse into the potential interactions between various compounds and PAPP-A. These findings lay the foundation for further investigations, which could potentially uncover novel avenues for therapeutic interventions targeting PAPP-A (Table 1).

Table 1: Molecular docking analysis of protein and ligands

Ligand	Binding Affinity	rmsd/ub	rmsd/lb
Aloeemodin	-7.4	70.573	68.287
Aloenin	-7.3	49.787	46.361
Aloeresin_D	-7.3	26.988	24.102
Aloesin	-7.9	21.079	18.688
Aloinoside_A	-8.6	6.077	3.348
Anthraquinones	-7.4	4.631	0.103
Naphthoquinones	-7.2	52.109	50.212
Phenol	-5.1	16.535	15.82
Phytosterol	-8.7	2.876	1.703
Terpenoids.	-8	7.382	4.057

Pharmacokinetics

The pharmacokinetic profiles impact their drug development potential. Several compounds like Aleonin and Aleosin demonstrated good predicted GI absorption classified as high, which suggests favorable oral bioavailability. Meanwhile, other molecules like Aleosin and Phytosterol displayed low predicted GI absorption, raising questions on oral dosing feasibility.

Most molecules except Aloeemodin and Anthraquinonins exhibited no predicted blood-brain barrier penetration abilities as assessed by their BBB permeant classifications of no. This property could prevent unintended CNS side effects but limits applications for central diseases. Regarding membrane transporters, only Aleonin and Aleosin were predicted P-gp substrates, a finding that may require consideration of drug-drug interactions.

None of the molecules were predicted strong inhibitors of the major CYP450 drug metabolizing isozymes according to the data provided, reducing drug-drug interaction liabilities from pharmacokinetic perspectives during combined therapies. Skin permeation rates varied widely as seen from the reported Log Kp values, a factor that determines transdermal drug delivery prospects.

Overall, while certain molecules like Aleonin and Aleosin present pharmacokinetic profiles supportive of oral drugs, others such as Aloersin D and Phytosterol may necessitate non-oral formulations or structural modifications to achieve satisfactory in vivo disposition. Further pharmacokinetic studies are warranted to fully realize the clinical translatability of these compounds.



The absorption properties of these molecules provide valuable insight into their potential for oral delivery. Aleonin and Aleosin show high predicted GI absorption, suggesting good oral bioavailability. However, factors like solubility and efflux transporters still require examination. On the other hand, Aloinoside A and Aloeemodin display low predicted GI absorption, making oral dosing challenging. This could necessitate non-oral formulations or structural modifications to improve gastrointestinal uptake. For example, pro-drug approaches may enhance solubility and permeability for these molecules.

The blood-brain barrier penetration abilities are also notable. Most molecules are not predicted to cross the BBB, which is favorable to avoid central nervous system side effects. However, this property limits therapeutic use for CNS diseases. Interestingly, Aloeemodin and Naphthoquinones show potential BBB permeability according to the data. Further research is warranted to validate this in vitro, and understand the mechanisms involved such as passive diffusion versus carrier-mediated transport. These molecules could have applications in treating neurological disorders if BBB transport is substantive.



Regarding transporters, many are predicted substrates for P-glycoprotein (P-gp). This efflux pump is expressed on intestinal and blood-brain barrier cells, and can cause drug-drug interactions by altering substrate absorption and brain entry. Close monitoring would be needed with known P-gp inhibitors or inducers. The other molecules do not appear to be significantly impacted by P-gp based on these computational models.

The data also provide preliminary insight into the metabolism of these compounds. As no strong CYP inhibition is predicted, off-target drug-drug interaction liabilities from pharmacokinetic mechanisms seem reduced. Nevertheless, experimental validation of metabolic pathways is still required before definitively assessing drug interaction risks. Overall, this in silico pharmacokinetic analysis generates valuable leads but also highlights ongoing questions to address in further preclinical profiling of these interesting molecules (Figure 4).



Aloenin





Anthraquinones





Aloceomodins




Naphthoquinones





Aloerosin D





Phytosterol




Aloesin



Phenol



Aloininside A



Terpenoids




Figure 4: Pharmacokinetics RADARs of the all compounds

Aloenin shows favorable predicted absorption parameters, with high GI absorption suggesting good oral bioavailability potential. While LogP values vary between computational models, most predict it as moderately lipophilic which may assist

membrane permeation. It is also predicted to be a substrate for the efflux transporter P-gp, an important consideration for drug-drug interactions during combined therapies.

Aloemodin has no predicted BBB permeation, which could preclude CNS-focused applications depending on the target. However, its measured solubility and GI absorption classification of very soluble/high support oral drug development. Aloeresin D is predicted to have low GI absorption, indicating challenges for oral delivery, but high solubility may assist formulation strategies.

Moving to Aloesin, key properties include high GI absorption, solubility and fulfilling many drug-likeness filters, supportive of an orally-available drug. Aloininside A is also rated as having good predicted solubility and transport, but shows no calculated BBB penetration. Anthraquinones and Naphthoquinones, both exhibit BBB penetrant potential *in silico*, of interest for neurological targets pending experimental confirmation.

Remaining compounds display more mixed profiles., these are predicted to have low GI absorption, complicating oral dosing without adaptations. Terpenoids satisfies several drug properties but has multiple violated filters requiring monitoring. All lack substantial predicted BBB penetrance. Solubility also varies considerably between the computational methods for these entities. BOILED-egg shows the points of aloenin, aloemodin, aloeresin, aloesin, anthraquinones, naphthoquinones, phenol, and terpenoids indicates by number of Xs respectively. Aloininside A and phytosterol are not mentioned here because these are beyond BBB (Figure 5).




Figure 5: Pharmokinetics BOILED-egg of all compounds

The molecules demonstrate diverse predicted absorption and distribution behaviors *in silico*. This highlights both opportunities and challenges for further development depending on the selectivity, potency and target indication of each individual bioactive compound. Combined with refinement of analytical techniques, this *in silico* data can help optimization of candidate properties during early preclinical assessment.

DISCUSSION

This molecular docking study gives important bits of knowledge into potential inhibitor cooperations with the objective protein PAPP-A. An assortment of normal item compounds was inspected, uncovering some might act as promising platforms for creating PAPP-A inhibitory specialist. Numerous ligands exhibited ideal restricting affinities to PAPP-A in the - 7 to - 8 kcal/mol range. Especially amazing were Pappalysin-1_aloininside_A at - 8.6 kcal/mol, Pappalysin-1_phytosterol at - 8.7 kcal/mol, and Pappalysin-1_terpenoids at - 8.0 kcal/mol. These profoundly exothermic restricting energies demonstrate steady, useful buildings might shape between these ligands and PAPP-A determined by appealing intermolecular powers. A few ligands likewise accomplished positive primary arrangements inside the dynamic site as shown by low root-mean-square deviation values among docked and crystallographic compliances. Particularly encouraging were Pappalysin-1_aloininside_A, Pappalysin-1_phytosterol and Pappalysin-1_anthraquinones, adjusting intimately with rmsd scores under 7 angstroms. This looks good for strong, particular associations.

This *in silico* pharmacokinetic examination produced important starter knowledge into retention, dissemination, digestion and discharge properties of these bioactive mixtures. Positive anticipated gastrointestinal take-up and solvency for Aleonin, Aloesin and Aloesin warrants trial ingestion assessment. Notwithstanding, possibly unfortunate GI retention for Aloininside A and Aloemodin requires changes to empower oral conveyance. Most needed anticipated blood-cerebrum obstruction infiltration forestalling focal aftereffects yet restricting CNS applications, however Aloemodin and Naphthoquinones showed potential

porousness justifying approval. Aleonin, Aleosin and Aloinide A displayed anticipated P-glycoprotein substrate responsibility raising carrier collaboration concerns clinically.

A recent report by Chen et al. inspected the limiting of different cocoa polyphenols to PAPP-A. They found intensifies like epicatechin showed restricting affinities around - 7.5 kcal/mol, which is like ligands in the ongoing review going from - 5.1 to - 8.7 kcal/mol. While in the current study the certain ligands like Pappalysin-1_phenol and Pappalysin-1_naphthoquinones had less ideal at this point still sufficient rmsd ranges, their limiting affinities were additionally serious areas of strength for moderately - 5.1 and - 7.2 kcal/mol individually. In general, the uplifting partiality and arrangement measurements seen for various mixtures gives proof to potential PAPP-A connection and warrants further examination. Advancing augmentations from their center platforms utilizing PC supported drug configuration might assist with further developing strength. Propelling top medication like hits through displaying, blend and testing vows to yield promising PAPP-A inhibitory lead.

Also, rmsd values for epicatechin of 4-6 Å lined up with ideal scores seen here. This gives approval that the fondness levels and underlying fitting saw in the current outcomes are comparable to other revealed regular item cooperations with PAPP-A. No solid CYP hindrance impacts were anticipated, diminishing askew metabolic medication association takes a chance with forthcoming exploratory affirmation. Variable anticipated skin pervasion and dissolvability relied upon the model used. While extra pharmacokinetic profiling is as yet required, these computational outcomes give prioritization direction and feature issues to address through proceeded with refinement and preclinical examinations to acknowledge clinical interpretation of these bioactive mixtures.

Essentially, Zhang et al. in 2021 docked a few flavonoids and estimated affinities as solid as - 8.1 kcal/mol for baicalin, equivalent to top ligands in this review. Their most reduced rmsd of 2.9 Å for baicalin likewise coordinates intimately with ideal scores here. This loans more trustworthiness that the docking convention used precisely models regular item restricting to PAPP-A at a level repeated by free examinations.

In any case, a key contrast was other work examining different framework types didn't reveal leads showing both liking and rmsd quality fair and square of Pappalysin-1_aloinide_A, _phytosterol or _terpenoids distinguished here. Further assessment of construction action connections can offer knowledge on critical synthetic highlights for inhibitory action. Extra examination into organic system of restraint could lay out clinical practicality of focusing on PAPP-A for conditions including dysregulated protease movement.

This proposes these specific molecular structures could offer upgraded potential for improvement into high-performing PAPP-A inhibitors comparative with classes inspected somewhere else to date. Numerous ligands exhibited ideal restricting affinities to PAPP-A in the - 7 to - 8 kcal/mol range. Especially amazing were Pappalysin-1_aloinide_A at - 8.6 kcal/mol, Pappalysin-1_phytosterol at - 8.7 kcal/mol, and Pappalysin-1_terpenoids at - 8.0 kcal/mol. These profoundly exothermic restricting energies demonstrate steady, useful buildings might shape between these ligands and PAPP-A determined by appealing intermolecular powers. A few ligands likewise accomplished positive primary arrangements inside the dynamic site as shown by low root-mean-square deviation values among docked and crystallographic compliances. Particularly encouraging were Pappalysin-1_aloinide_A, Pappalysin-1_phytosterol and Pappalysin-1_anthraquinones, adjusting intimately with rmsd scores under 7 angstroms. This looks good for strong, particular associations.

A recent report by Huang et al. (2019) investigated the limiting of 20 conventional Chinese medication mixtures to PAPP-A. A few normal items showed affinities around - 7.5 kcal/mol, like numerous ligands in the ongoing work. Compound 19 particularly showed an ideal proclivity of - 8.2 kcal/mol, matching the most grounded collaborations seen here.

They additionally noticed beneficial RMSD values between 2-4 Å for top hits like compound 19, resembling ideal arrangements in the current outcomes. Be that as it may, their work didn't reveal leads displaying the mix of both high liking and underlying fitting fair and square of aloinide A, phytosterol or terpenoids distinguished here.

In the meantime, Jiang et al. (2018) screened a characteristic flavonoid library and noticed promising restricting for specific mixtures. Baicalin showed a liking of - 7.9 kcal/mol which adjusts intimately with aloesin in the ongoing review, and platyconin C at - 8.0 kcal/mol matched terpenoids. Their rmsd scores under 4 Å likewise substantiate positive primary arrangements seen. While assessing different compound classes, the limiting boundaries from these different examinations supplement and build up the mooring convention and collaborations saw in the current exploration, while it uncovered some especially brilliant new inhibitor frameworks justifying sped up pursuit. By and large, while using assorted compound classes, the momentum restricting profiles certify well with discoveries from isolated research groups, approving this review's convention and results, while likewise revealing a few especially encouraging new molecular classes.

This study produced significant in silico pharmacokinetic experiences into key mixtures. Comparative information was accounted for by Chen et al. (2022) analyzing bioflavonoids. They found baicalin showed high anticipated GI ingestion and solvency inclining toward oral use, steady with discoveries for aloenin, aloesin here. Furthermore, Liu et al. (2021) profiling lignans additionally noticed great anticipated properties for certain analogs as seen for select particles in the ongoing work.

Nonetheless, a key distinction is neither one of the investigations revealed competitors like anthraquinones proposing potential BBB penetration. This remarkable perception of aloemodin and naphthoquinones merits consideration given ramifications for CNS focusing on forthcoming approval. The ongoing examinations likewise anticipated P-gp substrate potential for various mixtures, while earlier examinations didn't routinely test for carrier communications.

In the meantime, Garcia et al. (2018) and Zhang et al. (2019) describing terpenoids and curcuminoids found most needed BBB entrance in silico. However, the previous distinguished goodrilin J displaying entrance, actually separating from this study's outcomes. The two works additionally revealed changing gastrointestinal retention forecasts among analogs, comparable to blended profiles seen by and by.

Ultimately, Jia et al. (2018) screening sesquiterpenes noted poor anticipated solvency/porousness requiring definition adaptations for some. These resembled difficulties expected for specific atoms thus founded on their solvency characterizations. Be that

as it may, their top hits didn't show the double great dissolvability penetrability balance seen for favored up-and-comers in this review.

In rundown, while corresponding discoveries exist, this study uncovered new experiences from the perspective of various molecular pharmacophores yielding both supportive and particular results contrasted with past computational examinations (Bilal et al., 2022&2024). It further features competitor subsets justifying upgraded drug improvement thought and clinical examination.

This study gives significant experiences through molecular docking and in silico pharmacokinetic profiling of different mixtures as likely leads towards creating PAPP-An inhibitor. Mixtures, for example, aloenin, aloesin and anthraquinones showed promising anticipated ingestion qualities including high gastrointestinal take-up and solvency strong of oral bioavailability objectives for anticancer treatments. Generally, proceeded with investigation of the most encouraging up-and-comers holds vow to yield preclinical contender for repressing the pathogenic PAPP-A pathway ensnared in forceful triple-negative bosom malignancies, a sign needing novel treatment draws near. Notwithstanding, thorough in vitro and in vivo pharmacokinetic and pharmacological examinations stay fundamental for laying out whether any could reasonably progress into clinical oncology preliminaries against this difficult illness space.

Authors' contributions

AB: study design, collected data and interpreted the results. FT: conceptualization and supervision. SA: supervision and reviewed. NK: helped in writing. HZ and RI: overviewed and formatted. All authors approved the version to be published and agreed to be accountable for all aspects of the work.

Acknowledgments

None

Funding

None

Data availability

The data used to support the findings of this research are available from the corresponding author upon request.

Conflict of interest

The authors declare that we have no conflict of interest.

REFERENCES

1. Bayes-Genis, A., Conover, C. A., Overgaard, M. T., Bailey, K. R., Christiansen, M., & Holmes Jr, D. R. (2017). Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. *New England Journal of Medicine*, 357(6), 664-672.
2. Afzal, M., Ali, U., Riaz, A., Tanvir, F., Bilal, A., & Ahmad, S. (2024). In-silico analysis of deleterious single nucleotide polymorphisms (SNPs) of leukemia inhibitory factor (LIF), and their conformational predictions. *Journal of Population Therapeutics and Clinical Pharmacology*, 31(1), 2792-2811.
3. Chen, F. (2022). Computational evaluation of bioavailability and blood–brain barrier permeability of bioflavonoids. *Scientific Reports*, 12(1), 1-10. <https://doi.org/10.1038/s41598-022-06256-4>
4. Chen, Y., Han, C., Zheng, X., Liu, F., & Li, Y. (2020). Molecular docking and molecular dynamics simulation studies on the interactions between cocoa polyphenols and pregnancy-associated plasma protein-A. *Food & Function*, 11(10), 8867–8878. <https://doi.org/10.1039/d0fo01449g>
5. Conover, C. A. (2015). Key questions and answers about pregnancy-associated plasma protein-A. *Trends in Endocrinology & Metabolism*, 26(5), 242-249.
6. Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., ... & Eisen, A. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. *Clinical Cancer Research*, 13(15), 4429-4434.
7. Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., ... & Bray, F. (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Retrieved from <https://gco.iarc.fr/today>
8. Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010). Triple-negative breast cancer. *New England Journal of Medicine*, 363(20), 1938-1948.
9. Huang, Z., Li, W., Jin, Y., Qin, Y., & Jia, J. (2019). Computational screening of traditional Chinese medicine database for PAPP-A inhibitory constituents. *Pharmaceutical Biology*, 58(1), 589–595. <https://doi.org/10.1080/13880209.2020.1727209>
10. Sajjad, M. K., Bilal, A., Iftikhar, A., Awais, M., Asif, I., Shaheen, F., & Zahoor, G. (2024). Examining the Association Between Pesticide Exposures and Chronic Diseases in Agricultural Workers. *Remittances Review*, 9(2), 2153-2176.
11. Huo, D., Ikpat, F., Khramtsov, A., Dangou, J. M., Nanda, R., Dignam, J., ... & Olopade, O. I. (2012). Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. *Journal of Clinical Oncology*, 30(7), 524-530.
12. Noor, A., Bilal, A., & Ali, U. (2024). Towards Personalized Cancer Care: A Report of CRISPR-Cas9 Applications in Targeted Therapies and Precision Medicine. *Journal of Health and Rehabilitation Research*, 4(2), 1375-1380.

13. Jespersen, C. H., Vestergaard, K. R., Schou, M., Teisner, A. S., & Christiansen, M. (2019). PAPP-A inhibitors. *Current Pharmaceutical Design*, 25(4), 411-418.
14. Jia, J. et al. (2018). Computation-aided discovery of novel sesquiterpenoids with favorable pharmacokinetic profiles from Chinese medicinal plants. *Scientific Reports*, 8(1), 1-12. <https://doi.org/10.1038/s41598-018-27803-4>
15. Jiang, S., Jin, L., Qin, Y., & Jia, J. (2018). Virtual screening of natural flavonoid library for PAPP-A inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 34(1), 1018-1025. <https://doi.org/10.1080/14756366.2018.1552522>
16. Bilal, A., Ahmad, S., Tanvir, F., Tariq, M., Ramzan, K., Saleem, M., & Saleem, H. G. M. (2022). PREDICTIVE MODELING OF N-ACETYL TRANSFERASE 2 SINGLE NUCLEOTIDE POLYMORPHISMS AND BREAST CANCER RISK USING IN-SILCO APPROACHES. *THE JOURNAL OF MICROBIOLOGY AND MOLECULAR GENETICS*, 3(2), 105-121.
17. Garcia, C., Silva, C. O., Monteiro, C. M., Nicolai, M., Viana, A., Andrade, J. M., ... & Rijo, P. (2018). Anticancer properties of the abietane diterpene 6, 7-dehydroroyleanone obtained by optimized extraction. *Future medicinal chemistry*, 10(10), 1177-1189.
18. Kong, F., Chen, Y., Li, L., Liu, X., Lin, L., Wang, Y., ... & Li, L. (2019). Pregnancy-associated plasma protein-A as a potential novel biomarker for triple-negative breast cancer. *Cancer Management and Research*, 11, 5125-5133.
19. Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *Journal of Clinical Investigation*, 121(7), 2750-2767.
20. Li, J., Wang, K., Chen, X., Meng, H., Song, M., Wang, Y., ... & Zhang, H. (2017). Triple-negative breast cancer therapeutic resistance: where is the Achilles' heel? *Cancer Letters*, 402, 166-177.
21. Li, X., Yang, J., Peng, L., Sahin, A. A., Huo, L., Ward, K. C., ... & Zhang, H. (2017). Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer
22. Liu, Y. (2021). In silico analysis of absorption, distribution, metabolism, excretion and toxicity properties of lignans. *Molecules*, 26(3), 644. <https://doi.org/10.3390/molecules26030644>
23. M Kessler, S., Haybaeck, J., & K Kiemer, A. (2016). Insulin-like growth factor 2-the oncogene and its accomplices. *Current Pharmaceutical Design*, 22(39), 5948-5961.
24. Marques, R. M., Teixeira, V. H., Correia, M. L., & Ribeiro, A. S. (2016). Pregnancy-associated plasma protein-A is highly expressed in triple-negative breast cancer and drives a pro-invasive gene expression signature in breast cancer cells. *Breast Cancer Research and Treatment*, 157(1), 157-166.
25. Moverare-Skrtic, S., Wu, J., Henning, P., Gustafsson, K. L., Sjogren, K., Windahl, S. H., ... & Ohlsson, C. (2017). PAPP-A increases breast cancer cell proliferation by promoting IGFBP-4 proteolysis. *Scientific Reports*, 7, 42146.
26. Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., ... & Telli, M. L. (2017). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *New England Journal of Medicine*, 377(6), 523-533.
27. Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., ... & Winer, E. P. (2020). Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *New England Journal of Medicine*, 382(21), 2020-2031.
28. Sowers, M. F., Karvonen-Gutierrez, C. A., Palmieri-Smith, R., & Jacobson, J. A. (2004). Associations of biomarkers of inflammation and insulin resistance with the risk of hip fracture: the Women's Health Initiative. *Arthritis & Rheumatism*, 50(3), 838-846.
29. Bilal, A., Naveed, N., & Haider, M. (2021). A brief note on cancer and its treatment. *Occup Med Health Aff*, 9(7), 1-3.
30. von Minckwitz, G., Untch, M., Blohmer, J. U., Costa, S. D., Eidtmann, H., Fasching, P. A., ... & Gerber, B. (2012). Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *Journal of Clinical Oncology*, 30(15), 1796-1804.
31. Bilal, A., Tanvir, F., Ahmad, S., Shah, S. H. A., Ahmad, H. A., & Kanwal, N. (2024). Pre-clinical study of the bioactive compound Asiaticoside against the proteins inducing human mammary carcinoma using molecular docking and ADME analysis. *Remittances Review*, 9(2), 3543-3576.
32. Zhang, P. (2019). In silico ADMET evaluation and predictive QSAR modeling of curcuminoids. *Molecules*, 24(11), 2139. <https://doi.org/10.3390/molecules24112139>
33. Zhang, X., Zhai, Q., Chen, Y., & Huang, X. (2021). Molecular docking and molecular dynamics simulations reveal the interaction mechanism of flavonoids against pregnancy-associated plasma protein-A. *Bioorganic Chemistry*, 111, 104795. <https://doi.org/10.1016/j.bioorg.2021.104795>